EP400

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.